C

Celsion Corp
F:CBOC

Watchlist Manager
Celsion Corp
F:CBOC
Watchlist
Price: 0.286 EUR -10.63% Market Closed
Market Cap: 96.8k EUR

Celsion Corp
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Celsion Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
C
Celsion Corp
LSE:0HUZ
Operating Income
-$14.5m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
4%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Celsion Corp
Glance View

Market Cap
96.8k EUR
Industry
Biotechnology

Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.

CBOC Intrinsic Value
Not Available
C

See Also

What is Celsion Corp's Operating Income?
Operating Income
-14.5m USD

Based on the financial report for Sep 30, 2025, Celsion Corp's Operating Income amounts to -14.5m USD.

What is Celsion Corp's Operating Income growth rate?
Operating Income CAGR 10Y
4%

Over the last year, the Operating Income growth was 31%. The average annual Operating Income growth rates for Celsion Corp have been 15% over the past three years , 5% over the past five years , and 4% over the past ten years .

Back to Top